Mumbai, Feb. 10 -- Cosmo Pharmaceuticals N.V. (and Glenmark Pharmaceuticals (Glenmark) announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi(R) in the United Kingdom. Winlevi(R) is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Published by HT Digital Content Services with permission from Capital Market....